| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1992.10.10.1635 |
| P953 | full work available at URL | http://intl.jco.org/cgi/content/abstract/10/10/1635 |
| P698 | PubMed publication ID | 1403041 |
| P50 | author | Branimir Ivan Sikic | Q28215761 |
| P2093 | author name string | L. Jew | |
| A. M. Yahanda | |||
| B. L. Lum | |||
| J. Halsey | |||
| M. P. Gosland | |||
| N. A. Brophy | |||
| M. N. Ehsan | |||
| S. Kaubisch | |||
| K. M. Adler | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| multiple drug resistance | Q643839 | ||
| pharmacodynamics | Q725307 | ||
| phase I clinical trial | Q5452194 | ||
| cyclosporine | Q367700 | ||
| etoposide | Q418817 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1635-1642 | |
| P577 | publication date | 1992-10-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance | |
| P478 | volume | 10 |
| Q43417536 | A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. |
| Q72163473 | A phase I trial of high-dose oral tamoxifen and CHOPE |
| Q44280538 | A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia |
| Q53019740 | A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. |
| Q54185189 | A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. |
| Q42930123 | Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. |
| Q34327218 | Acute myeloid leukaemia in adults |
| Q54153548 | Acute tubular necrosis following high-dose cyclosporine A therapy. |
| Q40388183 | Anthracycline antibiotics in cancer therapy. Focus on drug resistance |
| Q40449518 | Antineoplastic agents. Drug interactions of clinical significance. |
| Q53852784 | Approaches to multidrug resistance reversal. |
| Q42319809 | CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration |
| Q33370478 | Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile |
| Q41112395 | Cellular drug efflux and reversal therapy of cancer |
| Q54187619 | Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. |
| Q37355856 | Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders |
| Q30234940 | Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions. |
| Q40464085 | Clinical Studies with Modulators of Multidrug Resistance |
| Q35620664 | Clinical relevance of P-glycoprotein in drug therapy |
| Q42284655 | Clinically relevant drug-drug interactions in oncology |
| Q41201529 | Clinically significant drug interactions with cyclosporin. An update |
| Q37334707 | Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. |
| Q44525292 | Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias |
| Q36116213 | Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. |
| Q33333473 | Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies |
| Q92288577 | Database of adverse events associated with drugs and drug combinations |
| Q54183821 | Dexverapamil to overcome epirubicin resistance in advanced breast cancer. |
| Q35608207 | Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know |
| Q52320711 | Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic response predictions. |
| Q36135012 | Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice |
| Q40694333 | Etoposide: current status and future perspectives in the management of malignant neoplasms |
| Q41937519 | Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples |
| Q40271710 | Future perspectives for the development of P-glycoprotein modulators |
| Q58869653 | G2677T and C3435T Genotype and Haplotype Are Associated With HepaticABCB1(MDR1) Expression |
| Q36292923 | High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours |
| Q28610020 | Human liver microsomal metabolism of paclitaxel and drug interactions |
| Q41214653 | In vivo pharmacological effects of ciclosporin and some analogues |
| Q54185360 | Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. |
| Q40978951 | Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein |
| Q38099040 | Interactions between oral antineoplastic agents and concomitant medication: a systematic review |
| Q36031211 | Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine |
| Q40464073 | MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. |
| Q35983126 | Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide |
| Q71742043 | Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide |
| Q33758413 | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) |
| Q54166252 | Modifiers of multidrug resistance |
| Q54183825 | Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. |
| Q41142663 | Modulation of multidrug resistance in multiple myeloma |
| Q54185542 | Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells. |
| Q45869623 | Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter |
| Q40464078 | Modulators of Multidrug Resistance: Preclinical Studies |
| Q34255292 | Molecular pathways: regulation and therapeutic implications of multidrug resistance |
| Q40464069 | Multidrug Resistance in Pediatric Malignancies |
| Q40535284 | Multidrug resistance (MDR) genes in haematological malignancies |
| Q41055142 | Multidrug resistance in acute myeloid leukaemia |
| Q72668199 | Multidrug resistance in cancer |
| Q41052675 | Multidrug resistance in cancer chemotherapy |
| Q28208049 | Multidrug resistance in cancer: role of ATP-dependent transporters |
| Q72261484 | Multidrug resistance in human cancer |
| Q41175781 | Multidrug resistance in pediatric oncology |
| Q54135665 | Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin. |
| Q40655988 | Multiple drug resistance, the MDR gene, and the law of maximum perversity as it applies to oncology: an hypothesis |
| Q47944360 | Obstacles to Brain Tumor Therapy: Key ABC Transporters |
| Q42390230 | P glycoprotein (P-gp) and drug resistance--time for reappraisal? |
| Q40694511 | Pharmacokinetic drug interactions with anticancer drugs. |
| Q43978086 | Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia |
| Q41440111 | Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes |
| Q35771512 | Pharmacokinetic optimisation of treatment with oral etoposide. |
| Q36079867 | Pharmacokinetics of doxorubicin co-administered with high-dose verapamil |
| Q40535280 | Pharmacologic circumvention of multidrug resistance |
| Q33187648 | Pharmacological effects of formulation vehicles : implications for cancer chemotherapy |
| Q72149427 | Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker |
| Q53897811 | Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. |
| Q33729158 | Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group |
| Q54183817 | Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. |
| Q36292342 | Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer |
| Q44797030 | Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. |
| Q89706708 | Prediction of Clearance in Children from Adults Following Drug-Drug Interaction Studies: Application of Age-Dependent Exponent Model |
| Q30444746 | Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. |
| Q39140289 | Renal Drug Transporters and Drug Interactions |
| Q34774854 | Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance |
| Q73794585 | Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine |
| Q35567287 | Strategies for reversing drug resistance |
| Q46886618 | Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients |
| Q40458699 | The Genetic Basis of Resistance to Cancer Chemotherapy |
| Q33490842 | The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. |
| Q41139560 | The clinical pharmacology of etoposide: an update |
| Q34013578 | The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery |
| Q77182829 | The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs |
| Q41030442 | The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions |
| Q54111832 | Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. |
Search more.